logo

Acceleron Pharma, Inc (XLRN)



Trade XLRN now with
  Date
  Headline
7/23/2018 7:03:55 AM Acceleron Announces Positive Preliminary Results From Part 1 Of The ACE-083 Phase 2 Trial
7/12/2018 7:04:39 AM Acceleron Pharma Says FDA Granted Orphan Drug Designation For ACE-083
7/5/2018 4:31:51 PM Acceleron Appoints Robert Zeldin As Chief Medical Officer
6/26/2018 7:06:45 AM Acceleron To Present Preliminary Data On ACE-083 At 2018 Annual Meeting Of The Peripheral Nerve Society
6/15/2018 7:00:23 AM Acceleron Announces Updated Results From Ongoing Phase 2 Trials Of Luspatercept In Beta-Thalassemia
6/4/2018 7:07:26 AM Acceleron Announces Updated Results From Ongoing Phase 2 Trials Of Luspatercept In Myelodysplastic Syndromes
5/24/2018 10:36:58 AM Prevail Therapeutics Appoints Francois Nader To Its Board
5/22/2018 7:00:22 AM Acceleron Begins PULSAR Phase 2 Trial Of Sotatercept In Pulmonary Arterial Hypertension
5/1/2018 7:07:34 AM Acceleron Receives FDA Fast Track Designation For ACE-083 In Facioscapulohumeral Muscular Dystrophy
2/28/2018 7:56:52 AM RBC Capital Markets Is Increasing Acceleron Pharma, Inc (XLRN) FY18 Rev. Estimate To 40.97 M From 39.40 M
2/28/2018 7:48:47 AM RBC Capital Markets Is Cutting Acceleron Pharma, Inc (XLRN) FY18 Estimate To -2.83 From -2.73
1/8/2018 9:07:00 AM Acceleron Reports Preliminary Results From Part 1 Of ACE-083 Phase2 Trial In Patients With Facioscapulohumeral Dystrophy